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ABSTRACT: Mismatches in DNA occur naturally during replication and as a
result of endogenous DNA damaging agents, but the mismatch repair
(MMR) pathway acts to correct mismatches before subsequent rounds of
replication. Rhodium metalloinsertors bind to DNA mismatches with high
affinity and specificity and represent a promising strategy to target
mismatches in cells. Here we examine the biological fate of rhodium
metalloinsertors bearing dipyridylamine ancillary ligands in cells deficient in
MMR versus those that are MMR-proficient. These complexes are shown to exhibit accelerated cellular uptake which permits
the observation of various cellular responses, including disruption of the cell cycle, monitored by flow cytometry assays, and
induction of necrosis, monitored by dye exclusion and caspase inhibition assays, that occur preferentially in the MMR-deficient
cell line. These cellular responses provide insight into the mechanisms underlying the selective activity of this novel class of
targeted anticancer agents.
Mismatches in DNA arise naturally as a result ofreplication errors, endogenous DNA damaging agents,
and spontaneous processes such as cytosine deamination. The
mismatch repair (MMR) pathway acts to correct mismatches
before subsequent rounds of replication, reducing the number
of DNA mismatches in the human genome from ∼1000 to ∼1.1
The loss of MMR carries dire consequences, including
increased mutation rates,2−4 carcinogenesis,5−8 and resistance
to a variety of clinical anticancer agents, such as antimetabolites,
DNA alkylators, and cisplatin.9−16 Furthermore, this resistance
to commonly used agents leads to enrichment of MMR-
deficient cells; roughly half of secondary leukemias show MMR
deficiency.17 These issues point to the need for a therapeutic
agent that specifically targets MMR-deficient cells.
Rhodium metalloinsertors have been developed in our
laboratory to target DNA mismatches in vitro (Figure 1).18−22
DNA mismatches, owing to their loss of hydrogen bonding and
poor stacking, are destabilized relative to well-matched DNA.23
It is this thermodynamic destabilization that our laboratory
seeks to exploit as a means of targeting mismatches, since
mismatches do not significantly perturb the structure of the
B-form DNA duplex.24−28 The width of the expansive aromatic
system of the chrysi ligand (chrysi = chrysene-5,6-quinonedii-
mine) exceeds the width of well-matched base pairs, 11.3 Å
versus 10.8 Å. As a result, complexes bearing the chrysi ligand
can be preferentially accommodated by DNA at thermodynami-
cally destabilized mismatch sites.20 In addition to their DNA
binding capabilities, these complexes promote single-stranded
cleavage of the DNA backbone upon photoactivation. This
photocleavage chemistry provides a useful tool to probe DNA
binding. Photocleavage titration experiments revealed that the
first-generation compound, [Rh(bpy)2chrysi]
3+, binds 80% of
DNA mismatches with typical binding constants of 106 M−1
and remarkable specificity for mismatched DNA; similar
experiments also showed single-site targeting of the mismatch
in a 2.7 kb DNA fragment.18,19 Subsequent work led to the
incorporation of nitrogen atoms into the intercalating ligand
and a 50-fold increase in binding affinity for the second
compound, [Rh(bpy)2phzi]
3+ (phzi = benzo[a] phenazine-5,6-
quinonediimine).20
A high-resolution crystal structure of [Rh(bpy)2chrysi]
3+
bound to single base mismatches within a DNA oligonucleotide
duplex reveals a distinctive binding mode at the mismatched
site.29 We had previously demonstrated that rhodium
intercalators bearing the phi ligand bind to well-matched DNA
by partial intercalation of the planar phi ligand from the major
groove side into the base pair stack.30 However, binding to the
mismatched site involves instead insertion of the more expansive
chrysi ligand into the DNA duplex from the minor groove side at
the mismatched site with ejection of the mismatched bases out of
the DNA stack; the inserted ligand stacks fully with adjacent base
Received: October 14, 2011
Published: November 21, 2011
Figure 1. Structures of rhodium metalloinsertors, [Rh(HDPA)2-
chrysi]3+ and [Rh(MeDPA)2chrysi]
3+.
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pairs. NMR studies confirm this metalloinsertion mode for the
complex at mismatched sites in solution.31 Further crystallo-
graphic studies revealed the generality of the metalloinsertion
binding mode; in independent views of metalloinsertion at four
different mismatch sites, the ejected bases superimpose
identically.32 It seems likely that such a perturbation of the
double helix might have consequences within the cell.
Of course, any potential agent must first reach its target
before it may bind. Confocal microscopy and flow cytometry
studies with [Ru(L)2dppz]
2+ (dppz = dipyrido[3,2-a:2′,3′-c]phen-
azine) analogues have demonstrated that cellular accumulation
occurs through passive diffusion, facilitated by the negative
potential difference across the cell membrane.33,34 Taken
together, the observations that (i) rhodium metalloinsertors are
capable of recognizing mismatches with high selectivity and (ii)
analogous ruthenium complexes accumulate within cells and
nuclei form a sound basis for the hypothesis that rhodium
metalloinsertors recognize mismatched DNA within cells and
predict that these complexes should selectively target MMR-
deficient cells, which harbor ∼1000-fold more mismatches than
MMR-proficient cells.
This predicted selectivity has been demonstrated in the
HCT116 cell lines.35,36 The HCT116N/HCT116O pair serve
as an isogenic model system for MMR deficiency, differing only
in the presence of an active copy of the MLH1 gene, which is
essential for MMR.37 Rhodium metalloinsertors were shown to
block selectively the growth of the repair-deficient HCT116O
cell line versus the repair-proficient HCT116N cell line, as
measured by an ELISA for DNA synthesis, which serves as a
proxy for cellular proliferation.38,39 Importantly, the difference
in activity between the cell lines correlates directly with the
binding affinity for DNA mismatches for a series of rhodium
metalloinsertors with varying ancillary ligands.36 This observa-
tion supports the idea that rhodium metalloinsertors bind to
DNA mismatches in cellulo as well as in vitro.
However, the proliferation assay does not distinguish
between senescence and cell death and therefore is insufficient
to demonstrate cytotoxicity. Here, we show that rhodium
metalloinsertors are preferentially cytotoxic to the MMR-
deficient HCT116O cell line. This rhodium-induced death is
shown to be necrotic rather than apoptotic and is preceded by
cell cycle arrest at the G1/S-phase boundary. This observation
is consistent with activation of the DNA damage response by
rhodium metalloinsertors.
■ EXPERIMENTAL PROCEDURES
Materials. RhCl3 was purchased from Pressure Chemical,
Inc. (Pittsburgh, PA). [Rh(NH3)5Cl]Cl2 was obtained from
Strem Chemical, Inc. (Newburyport, MA). 2,2′-Dipyridylamine
(HDPA) and Sephadex ion-exchange resin were obtained from
Sigma-Aldrich (St. Louis, MO). Sep-Pak C18 solid-phase
extraction cartridges were purchased from Waters Chemical
Co. (Milford, MA). Media and supplements were purchased
from Invitrogen (Carlsbad, CA). The 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) labeling reagant and
acidified lysis buffer (10% SDS in 10 mM HCl) were purchased
in kit format from Roche Molecular Biochemicals (Mannheim,
Germany). Z-VAD-FMK caspase inhibitor was purchased from
Promega. All PARP inhibitors were purchased from Santa
Cruz Biotechnology, Inc. All commercial materials were used as
received.
Synthesis of Metal Complexes. [Rh(HDPA)2chrysi]Cl3
was prepared according to previously described procedures.36
[Rh(MeDPA)2chrysi]Cl3 was synthesized by refluxing [Rh-
(NH3)4chrysi]TFA3 with 2 equiv of MeDPA in 1:1 ethanol:
water overnight. The ligand MeDPA was prepared by
deprotonation and methylation of HDPA (unpublished results
in the laboratory). The reaction mixture was cooled to room
temperature, and the solvent was removed under vacuum. The
desired product was isolated by cation exchange chromatog-
raphy with Sephadex CM-25 resin, eluting with 0.03 M
MgCl2(aq). Excess magnesium was removed by solid-phase
extraction with a Sep-pak C18 cartridge, and the TFA
counterion was exchanged for the chloride by anion exchange
chromatography with Sephadex QAE-125 resin. Formation of
the desired product was confirmed by UV/vis (H2O, pH 5):
295 nm (55 000 M−1 cm−1), 320 nm (39 700 M−1 cm−1),
390 nm (14 000 M−1 cm−1), and ESI-MS (cation): 727.1 m/z
([M − 2H]+), 364.3 m/z ([M − H]2+) obsd, 727.2 m/z
([M − 2H]+) calcd. Purity was confirmed by analytical HPLC
(tretention = 13.5 min, 10:90:0.1 MeCN:H2O:TFA to 40:60:0.1
MeCN:H2O:TFA over 45 min).
Cell Culture. HCT116N and HCT116O cells were grown
in RPMI medium 1640 supplemented with: 10% FBS; 2 mM
L-glutamine; 0.1 mM nonessential amino acids; 1 mM sodium
pyruvate; 100 units/mL penicillin; 100 μg/mL streptomycin;
and 400 μg/mL Geneticin (G418). Cells were grown in tissue
culture flasks and dishes (Corning Costar, Acton, MA) at 37 °C
under 5% CO2 and humidified atmosphere.
ICP-MS Assay for Cellular Rhodium Levels. Each cell
line was treated with 10 μM [Rh(bpy)2chrysi]
3+, [Rh(HDPA)2-
chrysi]3+, or [Rh(NH3)4chrysi]
3+ for 48 h. After rhodium
incubation, the cells were harvested from adherent culture by
trypsinization, washed with cold PBS, and counted by a
hemacytometer. The samples were pelleted and resuspended in
1% HNO3 (v/v), homogenized by three freeze/thaw cycles in
liquid nitrogen, and analyzed for rhodium content on an HP-
4500 ICP-MS unit. Rhodium counts were normalized to the
number of cells counted in each sample before lysate
preparation. Standard errors for three independent experiments
are shown.
Cellular Proliferation ELISA. HCT116N and HCT116O
cells were plated in 96-well plates at 2000 cells/well and
allowed 24 h to adhere. The cells were then incubated with
rhodium for the durations specified. For incubation less than
72 h, the Rh-containing media was replaced with fresh media,
and the cells were grown for the remainder of the 72 h period.
Cells were labeled with BrdU 24 h before analysis. The BrdU
incorporation was quantified by antibody assay according to
established procedures.38,39 Cellular proliferation was expressed
as the ratio of the amount of BrdU incorporated by the treated
cells to that of the untreated cells.
MTT Cytotoxicity Assay. Cytoxicity assays were per-
formed as described in the literature.40 HCT116N and
HCT116O cells were plated in 96-well plates at 50 000 cells/
well and incubated with rhodium for the durations specified.
After rhodium incubation, cells were labeled with MTT for 4 h
at 37 °C under 5% CO2 and humidified atmosphere. The
resulting formazan crystals were dissolved with solubilizing
reagant purchased from Roche according to the manufacturer’s
instructions. The dissolved formazan was quantified as the
absorbance at 570 nm minus the background absorbance at
690 nm. Percent viability was determined as the ratio of the
amount of formazan in the treated cells to that of the untreated
cells. For caspase inhibition assays, Z-VAD-FMK was added to
a final concentration of 20 μM. For poly-ADP ribose
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polymerase (PARP) assays, the inhibitor 3,4-Dihydro-5[4-(1-
piperindinyl)butoxy]-1(2H)-isoquinoline (DPQ) was added
to a final concentration of 0, 25, or 50 μM; the inhibitor
3-aminobenzamide (3-AB) was added to a final concentration
of 0, 2, or 3 mM; the inhibitor 4-amino-1,8-napthalimide
(4-AN) was added to a final concentration of 0, 10, or 20 μM;
and the inhibitor 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimida-
zole-4-carboxamide (ABT-888) was added to a final concen-
tration of 0, 5, or 10 μM.
Cell Cycle Distribution Flow Cytometry Assay. Cells
were harvested from adherent culture by trypsinization and
washed with cold PBS. The resultant pellet was resuspended in
PBS (chilled to 4 °C), and ice-cold ethanol was added dropwise
to a final concentration of 70% (v/v), with continuous gentle
agitation. Cells were fixed at 4 °C for 30 min and stored for up
to 1 week. Prior to analysis, the fixed cells in 70% ethanol were
diluted 1:3 in cold PBS and centrifuged at 1400g for 5 min.
The resultant pellet was washed twice and resuspended in ice-
cold PBS. Ribonuclease was added to a final concentration of
30 μg/mL, and the cells were incubated overnight at 4 °C. The
next day propidium iodide was added to a final concentration
of 20 μg/mL, and cells were analyzed by flow cytometry.
Data analysis was performed using the FloJo software package
(v 8.7.1).
Cell Death Mode Flow Cytometry Assay. Cell death
was characterized by a dye exclusion assay.41 After 24, 48, or
72 h incubation with rhodium, cells were harvested from
adherent culture by trypsinization, washed with cold PBS, and
centrifuged at 2000 rpm for 5 min. The resultant pellets were
resuspended in PBS to a concentration of 106 cells/mL and
stained with propidium iodide to a final concentration of 1 μg/mL
and with YO-PRO-1 to a final concentration of 200 nM for
30 min prior to analysis by flow cytometry.
■ RESULTS
ICP-MS of Whole Cell Lysates. Each cell line was treated
with 10 μM [Rh(bpy)2chrysi]
3+, [Rh(HDPA)2chrysi]
3+, or
[Rh(NH3)4chrysi]
3+ for 48 h. Whole cell lysates were analyzed
for rhodium levels by ICP-MS (Figure 2). As expected, the
HDPA complex exhibits a higher degree of cellular uptake than
the other complexes. This supports the notion that the early
activity displayed by the complex in the ELISA assay results
from accelerated uptake.36 It should be noted that these
treatment conditions directly reflect those used previously.
MTT Cytotoxicity Assay. The cytotoxicities of [Rh(HDPA)2-
chrysi]3+ and [Rh(MeDPA)2chrysi]
3+ were determined by MTT
assay.40 Briefly, reduction of the MTT reagant by mitochondrial
enzymes leads to the production of formazan, which can then be
dissolved in acidified SDS to produce a characteristic absorbance
at 570 nm. This absorbance reflects the relative metabolic
activity, which in turn reflects the percentage of viable cells in
each sample. HCT116N and HCT116O cells were plated and
treated with 0−25 μM [Rh(bpy)2chrysi]3+, [Rh(HDPA)2-
chrysi]3+, or [Rh(MeDPA)2chrysi]
3+ for 48 or 72 h. The results
are shown in Figure 3. At 48 h [Rh(HDPA)2chrysi]
3+ and
[Rh(MeDPA)2chrysi]
3+ clearly display an enhanced toxicity in
the MMR-deficient HCT116O cell line versus the HCT116N
cell line. For example, 72 h after treatment with 20 μM
[Rh(HDPA)2chrysi]
3+, the number of viable HCT116N cells
is 80 ± 5.2% of untreated controls, whereas the number of
viable HCT116O cells is 37 ± 4.4% of untreated controls.
[Rh(MeDPA)2chrysi]
3+ also shows differential toxicity against
the HCT116O cell line in this assay comparable to that of
[Rh(HDPA)2chrysi]
3+.
Cell Cycle Distribution. Given the observation that the
complexes inhibit DNA synthesis, a flow cytometry assay was
performed to determine if the cytotoxicity of [Rh(HDPA)2chrysi]
3+
is accompanied by disruption of the cell cycle.36 MMR-proficient
HCT116N and MMR-deficient HCT116O cells were treated with
20 μM [Rh(HDPA)2chrysi]
3+ for 24 or 48 h. After treatment, cells
Figure 2. ICP-MS assay for rhodium accumulation. Normalized
rhodium counts for whole cell lysates treated with 0 or 10 μM
[Rh(bpy)2chrysi]
3+, [Rh(HDPA)2chrysi]
3+, or [Rh(NH3)4chrysi]
3+ for
48 h. Standard error bars for three trials are shown. Cellular
concentrations were determined by counting on a hemacytometer
prior to lysis. Rhodium counts were normalized to total cells per
sample.
Figure 3. Selective toxicity of [Rh(HDPA)2chrysi]
3+ and [Rh-
(MeDPA)2chrysi]
3+ in MMR-deficient cells. HCT116N and
HCT116O cells were plated in 96-well format at densities of 5 ×
104 cells/well and treated with 0−25 μM [Rh(bpy)2chrysi]3+,
[Rh(HDPA)2chrysi]
3+, or [Rh(MeDPA)2chrysi]
3+. After 48−72 h,
the cells were labeled with MTT for 4 h. While the first-generation
complex [Rh(bpy)2chrysi]
3+ is nontoxic up to 72 h, the dipyridylamine
derivatives [Rh(HDPA)2chrysi]
3+ and [Rh(MeDPA)2chrysi]
3+ exhibit
toxicity specifically in the MMR-deficient HCT116O cell line at 48 h.
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were stained with propidium iodide (PI) and analyzed by flow
cytometry. The PI fluorescence reports the amount of DNA in each
cell and follows a bimodal distribution, where the first peak contains
cells with one copy of the genome, i.e., cells in G0/G1-phase, and
the second peak contains cells with two copies of the genome, i.e.,
cells in G2- or M-phase. Cells in S-phase occupy the region between
the two peaks. Figure 4 shows these distributions for both cell lines,
with or without rhodium treatment. In both cases, a decrease in the
area under the curve between the peaks can be seen, indicating a
depletion of the S-phase populations. Fitting the raw distributions to
G1-, S-, or G2/M-phases confirms the depletion of the S-phase
population, concomitant with an increase in the G1-phase
population. Notably, at this concentration of [Rh(HDPA)2chrysi]
3+
large differentials in both the ELISA and MTT assay were observed.
The changes to the cell cycle are more pronounced in the mismatch
repair deficient HCT116O cell line, which continues to grow
aggressively at 48 h (>50% S-phase) in the absence of rhodium
treatment, whereas growth of the HCT116N cell line slows slightly
as the density of the culture increases. Furthermore, the HCT116O
cell line also shows a significant increase in the G2/M population as
well as the G1 population.
Mode of Cell Death. To characterize the cell death
occurring in response to rhodium treatment, a dye exclusion
flow cytometry assay was employed.41 The assay differentiates
between live cells, dead cells, and cells undergoing apoptosis or
necrosis through concurrent staining with propidium iodide (a
dead cell permeable dye) and YO-PRO-1 (an apoptotic cell
permeable dye). By plotting the fluorescence of the YO-PRO-1
channel against the PI channel, a pattern emerges. Healthy cells
are seen in the lower left-hand corner of the plot. Apoptotic
cells exhibit higher YO-PRO-1 fluorescence but still exclude
propidium iodide, placing them in the upper left-hand quadrant
of the pattern. Dead cells admit both dyes and are therefore
seen in the upper right-hand quadrant of the image. Upon flow
cytometry analysis, cells can be classified as live, apoptotic,
necrotic, or dead by defining regions in the fluorescence plane
corresponding to each category.
The HCT116N and HCT116O cell lines were incubated
with 0−25 μM [Rh(HDPA)2chrysi]3+ for 24−72 h. After
harvesting the cells and staining with both PI and YO-PRO-1,
the cells were analyzed by flow cytometry to obtain raw
fluorescence data. Representative data for 20 μM rhodium
treatment for 72 h are shown in Figure 5. YO-PRO-1
fluorescence is shown on the y-axis, and PI fluorescence is
shown on the x-axis. The color scale represents the number of
cells, with blue indicating fewer cells at a given pair of
fluorescence levels and orange representing a greater number of
cells at a given pair of fluorescence levels. The raw data were
analyzed by gating the fluorescence events into one of four
categories, depending on the fluorescence levels of the two
dyes. Figure 5 also shows histograms of live, apoptotic, necrotic,
and dead cells for the HCT116N and HCT116O cell lines
based on the flow cytometry. Rhodium treatment was either 15
or 20 μM [Rh(HDPA)2chrysi]
3+ for 72 h. As before, rhodium
treatment alone induces necrosis preferentially in the MMR-
deficient HCT116O cell line; there is no significant change in
the percentage of cells in the apoptotic region in either cell line.
The effect is significantly more pronounced in the MMR-
deficient HCT116O cell line, which drops from 79 ± 3.8% to
37 ± 5.3% after treatment with 20 μM [Rh(HDPA)2chrysi]
3+,
versus the MMR-proficient HCT116N cell line, which shows a
minimal decrease in live cells from 62 ± 0.6% to 54 ± 5.1%
after treatment with 20 μM [Rh(HDPA)2chrysi]
3+.
Caspase Inhibition. As a complement to the dye exclusion
flow cytometry assay, the MTT cytotoxicity assay was repeated
in the absence and presence of the pan-caspase inhibitor
Z-VAD-FMK.42 This inhibitor works by irreversibly binding to
Figure 4. Cell cycle distribution assay. HCT116N (green) and
HCT116O (red) cells were treated with 20 μM [Rh(HDPA)2chrysi]
3+
for 24 or 48 h. After fixation and staining with PI, cells were analyzed
by flow cytometry. The raw distributions were analyzed for cell cycle
phase using commercially available software. Upon rhodium treatment,
the S-phase population is depleted, with a concomitant increase in the
G1-phase population.
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the active site of caspases. As before, the HCT116N and
HCT116O cell lines were treated with 0−30 μM of the
[Rh(HDPA)2chrysi]
3+ complex for 24−72 h. In addition, each
treatment was also combined with the inhibitor at a final
concentration of 20 μM (Figure 6). As before, the rhodium
complex exhibited selective toxicity in the repair-deficient
HCT116O cell line, with cell viability dropping to 9.7 ± 4.4%
after treatment with 30 μMmetal complex for 72 h, versus 63 ±
5.7% viability in the repair-proficient HCT116N cell line.
Addition of the caspase inhibitor at 20 μM offered no
protection from rhodium to the HCT116N cell line (63 ±
5.7% without inhibitor, 52 ± 9.8% with inhibitor) or to the
HCT116O cell line (9.7 ± 4.4% without inhibitor, 9.8 ± 7.8%
with inhibitor). At a final concentration of 40 μM, the caspase
inhibitor provided some protection from rhodium to the
HCT116O cell line (16 ± 10% without inhibitor, 28 ± 3.7%
with inhibitor), but this difference was small in relation to the
differential between the HCT116N and HCT116O cell lines
and roughly within error (data not shown).
PARP Inhibition. The MTT cytotoxicity assay was also
repeated in conjunction with a panel of poly-ADP ribose
polymerase (PARP) inhibitors: DPQ, 3-AB, 4-AN, and ABT-
888.43−46 As before, the HCT116N and HCT116O cell lines
were treated with 0 or 20 μM of the [Rh(HDPA)2chrysi]
3+
complex for 72 h, with or without one of the four inhibitors. In
each case, treatment with the inhibitor completely abolished the
selective MMR-dependent effects of the rhodium compound
(Figure 7), as determined by the difference between the
percentage of viable cells in the HCT116N cell line and the
percentage of viable cells in the HCT116O cell line. For
example, in the case of the compound DPQ, this difference was
43 ± 2.7% without inhibitor and 0.6 ± 3.0% with inhibitor.
Figure 5. Flow cytometry assay of cell death. (Top) HCT116N and
HCT116O cells were treated with 20 μM [Rh(HDPA)2chrysi]
3+ for
72 h. Rhodium treatment causes cells to move away from the origin,
along the necrotic pathway (lower branch of pattern). The effect is
more pronounced in the HCT116O cell line. (bottom) HCT116N
and HCT116O cells were treated with 15 μM or 20 μM
[Rh(HDPA)2chrysi]
3+ for 24−72 h. Rhodium treatment causes a
sharp decrease in the live population of the HCT116O cell line with a
corresponding increase in the necrotic and dead cell populations. Minimal
effect is seen in the HCT116N cell line. Thus, [Rh(HDPA)2chrysi]
3+
preferentially induces necrosis in the MMR-deficient HCT116O cell
line.
Figure 6. Caspase inhibition assay. HCT116N and HCT116O cells
were plated in 96-well format at densities of 5 × 104 cells/well and
treated with 0−30 μM [Rh(HDPA)2chrysi]3+ with or without 20 μM
of the pan-caspase inhibitor Z-VAD-FMK. After 24−72 h, the cells
were labeled with MTT for 4 h. The resulting formazan crystals were
dissolved by addition of 10% SDS acidified with 10 mM HCl, and
absorbance was measured at 570 nm. The caspase inhibitor confers no
protection from rhodium-induced toxicity in either cell line.
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Similar results are seen with each of the other three compounds
as well; taken together, these data implicate PARP in the
MMR-dependent response to [Rh(HDPA)2chrysi]
3+.
■ DISCUSSION
The direct correlation between the binding affinity of rhodium
metalloinsertors for DNA mismatches and the differential in
their activity between the HCT116N and HCT116O cell lines
fails to predict the high selective activity of [Rh(HDPA)2chrysi]
3+.
In light of the shorter incubations required for this com-
plex, it seemed likely that accelerated cellular uptake is a
contributing factor in the increased cellular response. As
[Rh(HDPA)2chrysi]
3+ is not luminescent, another method was
needed to examine its cellular uptake. The high atomic mass
and monoisotopic distribution of rhodium make the cellular
accumulation of rhodium metalloinsertors well suited to
analysis by inductively coupled plasma−mass spectrometry
(ICP-MS).47−49 ICP-MS affords a direct comparison of the
cellular accumulation of a series of rhodium metalloinsertors
after treatments similar to those applied in ELISA assays for
activity. The highest levels of cellular accumulation are clearly
seen for the complex bearing the HDPA ligand, which was expected
in light of the previous observation that [Rh(HDPA)2chrysi]
3+
exhibits increased antiproliferative activity against the HCT116
cell lines at shorter incubation times than other rhodium metal-
loinsertors. Significant activity is seen with [Rh(HDPA)2chrysi]
3+
in as little as 12 h, while [Rh(bpy)2chrysi]
3+ and [Rh(NH3)4chrysi]
3+
display no activity at this incubation time.
Rhodium metalloinsertors have shown differential antiproli-
ferative activity in an ELISA assay for DNA synthesis. This
assay directly reports on the amount of BrdU label incorporated
during DNA replication and, as such, does not distinguish
between cells that are viable but not replicating, e.g., G0 cells
that have exited the cell cycle and cells that are inviable or dead.
Therefore, this assay can be used to determine inhibitory, but
not cytotoxic, activity. In contrast, the MTT assay reports
directly on cell viability as measured by metabolic activity, with
the action of mitochondrial reductases catalyzing the cleavage
of the labeling agent MTT. Here cells that are viable still
produce signal, i.e., formazan absorbance, whether or not
they are actively dividing. Thus, this assay can distinguish
between senescence and true cell death, and the effects
observed in response to rhodium treatment are truly cytotoxic.
Importantly, the concentration ranges and incubation times
of the treatments applied in the MTT assays for
[Rh(HDPA)2chrysi]
3+ and the closely related complex
[Rh(MeDPA)2chrysi]
3+ (0−25 μM, 24−72 h) are identical to
those that inhibit DNA synthesis as seen by ELISA.
Accordingly, the result that [Rh(HDPA)2chrysi]
3+ and
[Rh(MeDPA)2chrysi]
3+ trigger cell death selectively in the
MMR-deficient HCT116O cell line versus the MMR-proficient
HCT116N cell line as measured by MTT assay represents a
significant advance in the development of these complexes as
anticancer agents; clearly, these agents are more potent than
previously considered. Although [Rh(bpy)2chrysi]
3+ does not
appear to be selectively toxic at these concentrations, it is likely
that this is due to differences in the kinetics of cellular uptake,
rather than fundamental differences in its mode of action as
compared to [Rh(HDPA)2chrysi]
3+, since both bind DNA
mismatches with equal affinity.36 For either activity assay, the
complex must first accumulate within the cell, and then cellular
response must be triggered. While [Rh(HDPA)2chrysi]
3+ displays
activity in ELISA after 12 h incubations, [Rh(bpy)2chrysi]
3+
requires 48 h or more to show significant differential activity.
In light of the higher levels of rhodium accumulation seen by
ICP-MS after treatment with the HDPA complex versus the
bpy complex, it seems likely that accumulation of the bpy
complex is delayed by ∼36 h relative to the HDPA complex.
Cellular responses that occur quickly after accumulation, such
as the inhibition of DNA synthesis, can still be observed within
the 72 h time frame of the ELISA assay, and both complexes
display activity. However, a lag time will exist between the
inhibition of DNA synthesis and the onset of cell death, and
when combined with the slow uptake of [Rh(bpy)2chrysi]
3+
(t > 48 h), cell death is delayed accordingly and cannot be
observed within the time frame of the MTT assay (also 72 h).
Figure 7. PARP inhibition assay. HCT116N and HCT116O cells were
plated in 96-well format at densities of 5 × 104 cells/well and treated
with 0 μM (“−”) or 20 μM (“+”) of [Rh(HDPA)2chrysi]3+ with or
without PARP inhibitor (“−” = 0 μM DPQ, 3-AB, 4-AN, or ABT-888;
“+” = 25 μM DPQ, 2 mM 3-AB, 10 μM 4-AN, or 5 μM ABT-888;
“++” = 50 μM DPQ, 3 mM 3-AB, 20 μM 4-AN, or 10 μM ABT-888).
After 72 h, the cells were labeled with MTT for 4 h. The resulting
formazan crystals were dissolved by addition of 10% SDS acidified
with 10 mM HCl, and absorbance was measured at 570 nm. All four
PARP inhibitors confer protection from rhodium-induced MMR-
dependent toxicity, reducing the differential activity significantly.
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The fact that the [Rh(MeDPA)2chrysi]
3+ complex displays
differential toxicity against the HCT116O cell lines comparable
to that of the [Rh(HDPA)2chrysi]
3+ complex suggests that it
shares the accelerated uptake of the HDPA complex. This was
certainly expected, as the complexes are almost identical, but
does address the question of uptake mechanism and clearly
refutes the hypothesis that accelerated uptake requires a
hydrogen-bonding interaction with the bridging secondary
amine of the HDPA ligand. More importantly, this suggests
that selective toxicity as a function of MMR competency is a
general property of rhodium metalloinsertors with dipyridyl-
amine ancillary ligands and establishes these ligands as the basis
for the development of the next generation of complexes.
Flow cytometry analysis reveals that cell death is preceded
by disruption of the cell cycle. Treatment with 20 μM
[Rh(HDPA)2chrysi]
3+ for 24 h leads to a marked depletion of
the S-phase population with a concomitant increase in the G1
population. These data suggest that the G1/S-phase DNA
damage checkpoint may be activated in response to rhodium
treatment. In the case of the HCT116O line, the G2/M-phase
population also increases in response to rhodium treatment.
This could represent a secondary checkpoint activation
occurring at the G2/M-phase transition and might signal a
“two-alarm fire” that accompanies the enhanced activity against
this cell line.
The biochemical events associated with apoptosis have been
extensively studied.50 An extensive network of regulatory
proteins controls the initiation of this process in response to
both internal and external signals.51 Upon activation, the
cascade of initiator and effector caspases cleaves a variety of
substrates to bring about the morphological changes associated
with this mode of cell death, including nuclear condensation
and fragmentation, plasma membrane blebbing, decomposition
of the cell into apoptotic bodies, and ultimately the engulfment
of these bodies by neighboring cells through phagocytosis.52
Importantly, apoptotic cells retain their membrane integrity
until the very last stages of this process, preventing release of
cytokines and thus avoiding inflammation. By comparison, both
the causes and the progression of necrosis are much less
defined at the molecular level, and this mode of cell death is
most frequently characterized by morphological criteria.52−54
Perhaps the most reliable marker of necrosis then is the early
rupture of the plasma membrane, in direct contrast to
apoptosis. These differences in membrane integrity enable the
facile characterization of cell death by flow cytometry. The
admission of the dead cell stain propidium iodide by the
HCT116 cell lines upon rhodium treatment reveals that cell
death proceeds through a necrotic rather than apoptotic
pathway. This conclusion is supported by the observation that
the caspase inhibitor Z-VAD-FMK is unable to block rhodium-
induced toxicity in the MTT assay, indicating that death occurs
in a caspase-independent fashion.
It is interesting to consider that rhodium metalloinsertors
selectively induce necrosis in MMR-deficient cells. Tradition-
ally, necrotic cell death has been considered to be “accidental”,
occurring mainly in response to nonphysiological insults.55,56
More recently, however, the notion that necrosis may in fact
be an ancestral mode of programmed cell death has gained
attention in the literature and community of cell death
research.52,53,57 Hitomi et al. screened an siRNA library
covering the mouse genome and identified 432 gene
knockdowns that blocked the induction of necrosis.58 Chan
et al. found antinecrotic proteins encoded in the genomes of
several viruses.59 While these studies present some of the
most compelling evidence for the notion that necrosis is in
fact a regulated process, several other groups are also working
to provide a molecular definition for the process as has been
done for apoptosis.56,57
Thompson and co-workers have reported that the DNA
repair protein polyADP-ribose polymerase-1 (PARP-1) medi-
ates the induction of necrosis in response to DNA damage by
the alkylator MNNG.60 Upon activation at sites of DNA
damage, PARP-1 covalently modifies itself with long chains of
ADP-ribose polymers in order to recruit downstream
components of the repair machinery.61 As a result, PARP-1
along with PARP-2 has attracted much attention as a
therapeutic target recently, and several specific and potent
inhibitors of the enzyme are currently in clinical trials.62 Here,
treatment with a panel of PARP-1 inhibitors confers protection
from MMR-dependent toxicity, abolishing differential activity
between the HCT116 cell lines by Rh. This result strongly
suggests that PARP activation is required for the differential
biological effects of rhodium metalloinsertors. Importantly, the
fact that each of the four PARP inhibitors on the panel
abolishes differential activity argues against the notion that off-
target effects of any particular inhibitor are responsible for
blocking rhodium activity. Although the role of PARP in
regulating necrosis is still emerging, the requirement for PARP
activation is consistent with the notion that these rhodium
complexes elicit a damage response upon binding to DNA
mismatches. This is supported by flow cytometry analysis that
reveals cell death is preceded by disruption of the cell cycle.
Upon rhodium treatment, there is a sharp decline in the
population of cells that are actively synthesizing DNA. This
observation suggests that the G1/S-phase DNA damage
checkpoint is activated.
As necrosis triggers a pro-inflammatory response by releasing
cytokines, selective induction of necrosis in cancerous tissues
may be a way to activate the immune system against cancer
cells and ultimately improve efficacy of a therapeutic agent.63
One accepted trigger of necrosis is bioenergetic catastrophe,
i.e., severe ATP depletion.55,56 Rhodium metalloinsertors might
trigger such a catastrophe by targeting mitochondrial DNA.
Previously, it was thought that damaged mitochondrial
genomes simply would be degraded and replaced by the
replication of undamaged DNA.64 However, emerging research
has uncovered DNA repair processes in mitochondria,
including mismatch repair capability.64,65 As lipophilic cations,
rhodium metalloinsertors likely accumulate in mitochon-
dria,66−71 as we have seen with analogous ruthenium complexes
in our laboratory.33 If mitochondrial DNA mismatches are in
fact a target for rhodium metalloinsertors, then the resultant
disruption of mitochondrial function would lead to energy
depletion and necrosis. Future mechanistic work must explore
the biochemical consequences of mismatch binding in nuclear
DNA versus mitochondrial DNA. It should be noted that these
mechanisms are not mutually exclusive; as such, both might
contribute to the biological response to rhodium metal-
loinsertors.
These studies support the notion that rhodium metal-
loinsertors bearing HDPA ligands benefit from increased
cellular accumulation and thus provide an explanation for the
observation that [Rh(HDPA)2chrysi]
3+ exceeds the activity
predicted by its binding affinity for DNA mismatches.
This increased uptake allows us to observe additional cellular
responses to these agents, and, as a whole, a picture of the
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biological response to rhodium metalloinsertors, exemplified by
[Rh(HDPA)2chrysi]
3+ in particular, is beginning to emerge
(Figure 8). Over the course of the first 12 h, the rhodium
complex accumulates in cells, binding to either mitochondrial
or genomic DNA mismatches. Within 24 h, DNA synthesis is
inhibited, and cells accumulate in the G1-phase. Over the next
24−48 h, the DNA damage response is likely activated, and
ultimately leads to cell death by a caspase-independent, necrotic
mechanism. These biological effects are more pronounced at
each stage of the response in the MMR-deficient HCT116O
cell line relative to the MMR-proficient HCT116N cell line,
strongly suggesting that DNA mismatches are in fact the
cellular target of rhodium metalloinsertors.
This work shows that dipyridylamine ancillary ligands serve
to accelerate the cellular uptake of rhodium metalloinsertors,
triggering a selective cytotoxic effect as a function of MMR
status and forming the foundation for the next generation of
complex development. This new class of agents is significantly
more potent than previously considered, and the work begun
here on understanding their mechanism of action advances
their development as novel anticancer agents.
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